Loading…
for educational and safety purposes
TAK-653 and IDRA-21 both come up in the same conversations; they overlap on Glutamate. TAK-653: TAK-653, also called osavampator or NBI-1065845, is an experimental oral drug that makes the brain's main excitatory receptor, the AMPA glutamate receptor, respond more strongly to glutamate the brain is already releasing; crucially it cannot switch the receptor on by itself, a design choice intended to avoid the seizure risk that stopped earlier drugs of this type. IDRA-21: IDRA-21 is a small synthetic molecule derived from the blood pressure drug diazoxide.
TAK-653, also called osavampator or NBI-1065845, is an experimental oral drug that makes the brain's main excitatory receptor, the AMPA glutamate receptor, respond more strongly to glutamate the brain is already releasing; crucially it cannot switch the receptor on by itself, a design choice intended to avoid the seizure risk that stopped earlier drugs of this type. It is being developed as a fast-acting antidepressant for people whose depression has not responded to standard antidepressants. A 183-person Phase 2 trial found that 1 mg once daily beat placebo on a standard depression rating scale while 3 mg did not reach statistical significance, and five Phase 3 trials are now enrolling; those Phase 2 results have not yet been published in a peer-reviewed journal. It is approved nowhere in the world, it is not a legal supplement, and the entire published literature amounts to about ten papers, most of them written by employees of the companies that own it.
IDRA-21 is a small synthetic molecule derived from the blood pressure drug diazoxide. It does not switch brain receptors on by itself; instead it makes the AMPA receptor, which handles the brain's main fast excitatory signal, stay open longer once that natural signal arrives. Oral dosing improved memory scores in rats and in three separate monkey studies, which is why it is sold as a research chemical marketed for cognition. The evidence stops there; no person has ever been studied in a published trial, no clinical trial is registered, and no dose, blood level or side effect profile in humans has ever been reported. One rat study found it made hippocampal cell death after a stroke-like insult worse rather than better, so the safety picture is genuinely open.
both fingerprints on one instrument; where the marks line up the two compounds work the same lever, where a slot goes dark only one of them touches it. read straight from each entry's affinity table; nothing here is invented.
positive allosteric modulator; potentiates glutamate-evoked currents only when glutamate is present, with minimal intrinsic agonism
positive modulator
Off-target enzyme inhibition; the only hit in a 97-target screening panel at 10 uM
Downstream consequence of AMPA receptor potentiation, not a binding target; increased phosphorylated mTOR, p70S6K, Akt and ERK and raised BDNF protein in rat primary cortical neurons
Positive allosteric modulator; binds only in the presence of glutamate, at the intradimer interface in the channel-closed state, sterically gated by Ser750 in GluA2o (Ser743 in GluA1i)
No binding; TAK-653 does not displace [3H]-AMPA and instead mildly enhances its binding, confirming it is not an agonist
raises BDNF protein in rat primary cortical neurons and in a primate chronic-stress model
binds at the dimer interface and stabilizes the active conformation; structural interference at Ser743 is what keeps agonistic activity low
No prominent subunit selectivity across homomeric AMPA receptor subtypes
Potentiates glutamate-evoked Ca2+ influx in hGluA1i-expressing CHO cells; no effect without glutamate
increases phosphorylation in cortical neurons secondary to AMPA-R activation
Potentiates AMPA-evoked Ca2+ influx in rat primary hippocampal neurons
Potentiates AMPA-elicited whole-cell currents in rat primary hippocampal neurons
facilitates
Mixed and modest. Inhibits currents evoked by exogenous GABA while slightly prolonging autaptic GABAergic currents; net direction depends on the preparation.
Binds within the LBD dimer interface and stabilises the agonist-bound dimer against dissociation. Hydrogen-bonds to Ser754, which underlies the partial selectivity of benzothiadiazides for the flip splice form.
boosts calcium
Negative modulator. Reduces whole-cell NMDA currents non-competitively and voltage-independently, shortens NMDA-mediated mEPSC decay, and is more effective at GluN1a/GluN2B than GluN1a/GluN2A. Effect is stronger at low glycine, suggesting interaction with the glycine site.
strengths are the entries' qualitative ratings (strong / moderate / weak); Ki and EC50 figures appear where an entry records them.
easiest to source: TAK-653 is currently listed by more trusted vendors (2), so it's the simpler one to get hold of. for effects and safety, read each full entry; this is educational, not medical advice.